InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) AV-101 to Receive Patent from EPO to Treat Neuropathic Pain
Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has received a notice of intention to grant a patent from the European Patent Office (“EPO”). The notice is regarding the use of AV-101, the company’s investigational oral prodrug of 7-chloro-kynurenic acid (“7-Cl-KYNA”), in the treatment of…